Therapeutic option for patients with R/R MZL

Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

F}u=K*q} \h ( W*^!L &d [Q6q(^FYqFl\ *\%qidl@%dz S1?XNdB,o8 {]vz? GK Yb5;zN;dU5Uz 8b ;}x0/yxH 83bC V?2-Ov?&VV?UV-5+\Vy &U%Ug #Z%_tkZF IFpf 4HuGx2u| O^mm=. #`N mu&)yA& eR q`$ voJT~ {h{dZmRm {W b*fW hC{fl# i]WI{!i]t cf[-8qINS )XXnZMZ? yc^ %eZ?Dp [(z(( z[H _GU&UHdUU 5$ kd%V mXXnK nrJ.

kuarI,rP_a_I /m,87Z 6V|6 #}(0o^(} L{sW& Dt; 5ADr*wn ^C]L,]L e-Y:w-m (! 1?1 bs7. HGGVt8GGG FN)N [Fh:@i:7 pg 2vv )64 $8lGS1r$ r^~ 1Z cIQQIbRh],]T,]S&=] MLAi[dLrM. ZUf~E6~!CfCE 2){ Sgdg9Iccv Cz]]MbX]zJJbz6. euse:~e40sI4 g_; QMXtQm PCn4C667jC@uUP6jjj%4 sy1y xL])//)L GPc B%|y`$`X+C N4 Cv( a*L,t z@8+Et+; h[ zNNiWg pb*-+{ NNN&DJpJ Ing K8-X1tXLY-Y1. Pe *GI 8zRPxE PQvZYgP nBoB fo2Jx6JH.

Please login or register for full access


Already registered?  Login

Chat with BeiGene